Mohn Cancer Research Laboratory
Personalized cancer therapy

Promising results for hormone therapy

Through the Petremac study, doctors at Haukeland have found that patients with hormone-sensitive breast cancer have a good effect, fewer side effects and need less invasive surgery when they receive hormone treatment instead of chemotherapy.

Aas og Eikesdal
Senior Consultant Oncologist Turid As and Professor/Senior Consultant Oncologist Hans Petter Eikesdal.
Helse Bergen

Main content

With research funding from the Grieg Foundation, doctors at the Department of Cancer and the Department of Surgery have taken a closer look at how they can give patients with hormone-sensitive breast cancer the best possible treatment without having to undergo unnecessary and stressful chemotherapy and surgery.

Reduces the tumor
- Patients with larger cancer tumors currently receive primary drug treatment (hormone-blocking medication or cytotoxic drugs) to reduce the cancerous tumor, and then receive the necessary surgery afterwards. With a good effect of drug treatment, one can then avoid removing the entire breast (breast-conserving treatment), and also do gentle surgery in the armpit, says chief physician and professor Hans Petter Eikesdal at the Cancer Department at Haukeland.

For an extended presentation of the results, follow the link to Helse Bergen.